Host: Paul Doghramji, MD

Guest: Alex Spira, MD, PhD, FACP

Guest: John Longshore, PhD, FACMG

In the current era of cancer care, we’ve come to realize that non-small cell lung cancer is a disease of the genome. And now that advances in genomic profiling have enabled the identification of emerging biomarkers such as KRAS G12C oncologist Dr. Alex Spira and pathologist Dr. John Longshore are here to give us a closer look at the guideline recommendations for biomarker testing as well as best practices for overcoming real-world issues.

© 2020 Amgen Inc. All rights reserved. USA-510-80117 10/2020